468.41
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$460.83
Offen:
$464.33
24-Stunden-Volumen:
1.15M
Relative Volume:
0.76
Marktkapitalisierung:
$120.29B
Einnahmen:
$11.10B
Nettoeinkommen (Verlust:
$-988.90M
KGV:
-119.49
EPS:
-3.92
Netto-Cashflow:
$-1.26B
1W Leistung:
-0.37%
1M Leistung:
+6.14%
6M Leistung:
+6.09%
1J Leistung:
-5.97%
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
2024-11-14 | Eingeleitet | Citigroup | Buy |
2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
2023-05-30 | Eingeleitet | William Blair | Outperform |
2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
2023-03-21 | Eingeleitet | Bernstein | Outperform |
2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-01-27 | Bestätigt | JP Morgan | Overweight |
2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
2022-01-27 | Bestätigt | Stifel | Hold |
2022-01-27 | Bestätigt | Wolfe Research | Outperform |
2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-09-09 | Herabstufung | Stifel | Buy → Hold |
2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-20 | Eingeleitet | Bernstein | Outperform |
2020-10-28 | Eingeleitet | UBS | Buy |
2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
2019-11-12 | Eingeleitet | SunTrust | Buy |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
2019-08-01 | Herabstufung | Needham | Buy → Hold |
2019-05-23 | Fortgesetzt | Citigroup | Buy |
2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
2019-04-12 | Eingeleitet | Evercore ISI | In-line |
2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - TradingView
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals' (VRTX) Upcoming Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential Amid Pipeline Advancements and Financial Resilience - AInvest
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com
What institutional investors are buying Vertex Pharmaceuticals Incorporated stockAI Powered Entry Points That Work - jammulinksnews.com
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN
The 3 Things That Matter for Vertex Pharmaceuticals Now - AOL.com
The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Rapid growth opportunities - jammulinksnews.com
Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com
Published on: 2025-07-27 22:21:17 - jammulinksnews.com
Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com
Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN
Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize
What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional
Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com
Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance
What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail
Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve
Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest
Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):